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patients and 201 weeks for SCR patients. Factors differentiating
the BuMelTT and SCR groups included median followup post-
ASCT, total percent relapse after transplant, death after transplant,
relapse in prior radiation ﬁeld, and stage at salvage therapy pre-
ASCT. To date, 37% of the BuMelTT and 56% of SCR patients
have relapsed (P  .05) with a median time to relapse of 30 and 36
weeks (P  NS), respectively. Median OS, EFS, and RFS have not
yet been reached for BuMelTT patients compared with 439 (P 
.03), 67 (P  NS), and 74 (P  NS) weeks for the SCR patients
respectively. TRM was 5% in both groups at 5 years. Secondary
myelodysplasia has been seen in one patient transplanted with
BuMelTT and one with SCR. In multivariate analysis the
BuMelTT regimen and chemosensitive disease were associated
with improved OS (HR  0.19 and 0.31, respectively). Relapse in
prior radiation ﬁeld predicted for poor EFS and OS (HR  3.43).
We investigated the predictive value of 4 PM on the entire group,
BuMelTT and SCR cohorts. Each of these models has identiﬁed 3
poor prognostic indicators on the basis of multivariate analysis.
Patients with 0 or 1 factor were considered good risk and 2 or 3
factors poor risk. Only the SWOG model was predictive for OS for
the entire group (P  .01) and for the BuMelTT (P0.05) and
SCR (P  .01) cohorts. The SWOG model was also able to
differentiate EFS between good and poor risk patients for the
entire group (P  .02) and SCR group (P  .05) but not for the
BuMelTT cohort. None of the models could differentiate between
good and poor risk patients with regard to RFS. When good and
poor risk was deﬁned as 0 factors versus 1 to 3 factors, the RPCI
model was predictive of OS (P  .02) and EFS (P  .02) but only
for the BuMelTT cohort. The PM evaluated had limited utility in
our patient cohort with only the SWOG model being predictive of
outcome. Large multi-institutional studies are needed to improve
PM for transplantation in advanced HD.
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PACLITAXEL FOLLOWED BY FILGRASTIM FOR PERIPHERAL BLOOD
STEM CELL (PBSC) MOBILIZATION IN PATIENTS WITH HEMATOLOGIC
MALIGNANCIES WHO EXPERIENCED PRIOR MOBILIZATION FAILURES
McKibbin, T.1,2, Burzynski, J.A.1,2, Twombly, R.G.1,2, Ochoa, J.L.1,2,
Tsai, T.W.1,2, Callander, N.S.1,2, Freytes, C.O.1,2 1. South Texas
Veterans Health Care System, San Antonio, TX; 2. University of Texas
Health Science Center, San Antonio, TX.
Cyclophosphamide followed by ﬁlgrastim (G-CSF) is frequently
utilized for PBSC mobilization in patients with hematologic ma-
lignancies, but is associated with adverse events such as hemor-
rhagic cystitis and a rate of febrile neutropenia as high as 30%. In
addition, white blood cell recovery varies among patients making it
difﬁcult to predict when to initiate apheresis. Our institution pre-
viously reported the efﬁcacy of paclitaxel followed by G-CSF for
PBSC mobilization in 30 patients with hematologic malignancies.
In 86% of those patients, paclitaxel mobilization was the initial
mobilization attempt. We report our experience with paclitaxel
250 mg/m2 IV once followed by G-CSF 10-16 mcg/kg/day in 27
consecutive patients treated at Audie L. Murphy Memorial Veter-
ans Hospital between 1/98 and 9/05. Twenty-one (78%) failed
mobilization with G-CSF 16 mcg/kg/day alone, 5 (18%) failed
mobilization with cyclophosphamide 3 g/m2 followed by G-CSF,
and 1 (4%) failed mobilization with rituximab, ifosfamide, carbo-
platin, and etoposide followed by G-CSF. Eight patients had mul-
tiple myeloma (MM), 17 had non-hodgkin’s lymphoma, and 2 had
acute myelogenous leukemia. Similar to our prior experience, 74%
of patients began apheresis on day 8 after paclitaxel administration,
based on a rising peripheral white blood cell count. The remaining
patients began apheresis on day 9 or 10 after paclitaxel adminis-
tration. Eighteen (67%) of 27 patients collected the target number
of CD34cells, deﬁned as 2  106 cells/kg. An additional 4
patients underwent PBSC transplant with fewer than 2  106
CD34 cells/kg (median 1.83, range 1.43&ndsh;1.98). One pa-
tient successfully collected adequate PBSC but elected to undergo
allogeneic PBSC transplant; thus 21 (78%) of 27 patients pro-
ceeded to high-dose chemotherapy followed by autologous PBSC
transplant. Median neutrophil (ANC 	 0.5  109/L) and platelet
(platelet20 109/L) recovery was 11 days (range 8–12) and 13 days
(range 9–24), respectively. Three patients (11%) developed febrile
neutropenia following paclitaxel resulting in one death prior to
high-dose chemotherapy in a patient with MM. Conclusions:
Paclitaxel followed by G-CSF is an effective mobilization strategy
for patients with hematologic malignancies who failed to mobilize
PBSC with other mobilization regimens. The low incidence of
febrile neutropenia and the predictable kinetics of white blood cell
recovery make this combination an attractive alternative for pa-
tients who fail to mobilize PBSC.
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HIGH-DOSE CHEMOTHERAPY (HDCT) WITH HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH POOR PROGNO-
SIS EWING FAMILY TUMORS (EFT)
Bolotin, E.1, Shakhnovits, M.1, Cooper, L.1, Qian, D.1, Hitt, D.,
Sweetman, R.1, Sato, J.K.1, Miser, J.1, Forman, S.1, Rosenthal, J.1 City
of Hope National Center and Beckman Research Institute, Duarte, CA.
Objective: To evaluate the feasibility and safety of treatment
with two cycles of HDCT followed by autologous HSCT in
patients (pts) with poor prognosis EFT. A retrospective analysis
included 20 EFT pts treated at City of Hope National Medical
Center with 2 cycles of HDCT and HSCT from 1997 to 2003.
HDCT for the ﬁrst cycle consisted of melphalan (MEL)/carbopla-
tin (CARB) in 9 pts and Mel/busulfan (BU) in 11 pts. HDT for the
second cycle consisted of MEL/CARB (n  5); MEL/BU (n  3);
and cyclophosphamide/etoposide/CARB (n  5). A descriptive
analysis of the safety, rate of recurrence, transplant-related mor-
bidity (TRM) and mortality, event-free survival (EFS), and overall
survival (OS) are reported. Results: Out of 20 eligible patients, 13
(65%) received 2 cycles of HDCT followed by autologous HSCT.
Seven (35%) patients did not proceed to a second cycle as planned:
2 (28.5%) patients refused, 2 (28.5%) patients died of rapidly
progressive disease, 1 (14%) patient died of idiopathic pulmonary
ﬁbrosis, 1 (14%) patient had previous radiation, and 1 (14%)
patient had renal failure. The median follow-up (n  20) was 2.4
years (range 0.1–7.8 years). Grade 4 adverse events were limited to
mucositis and pancytopenia. No TRM was recorded after the ﬁrst
cycle of HDT and HSCT. There was one death after second cycle
due to rapidly progressive disease. A sustained absolute neutrophil
count (ANC 	 1000/mm3) for both cycles was achieved at the
median of 11 days. A sustained platelet count (	50,000/mm3) was
achieved at a median of 17 to 20 days. There were no differences
in OS rates between various HDCT regimens used and between
patients with or without metastatic disease disease at the time of
diagnosis. The Kaplan-Meier estimates of OS and EFS at three
years were 45% (CI 0.22, 0.69) and 47% (CI 0.25,0.70), respec-
tively. For patients who have received two cycles of HDCT fol-
lowed by HSCT, the Kaplan-Meier estimates of OS and EFS at 3
years were 58% (CI 0.30, 0.86) and 58% (CI 0.30, 0.86), respec-
tively. Conclusions: Dose-intensiﬁcation with two cycles of
HDCT and HSCT is feasible and relatively safe, with low and
acceptable treatment related morbidity and mortality. Adding a
second course of therapy does not impair engraftment. Both OS
and EFS compare favorably with previously published reports.
HDCT with HSCT may improve outcome in patients with poor
prognosis EFT. Further studies are required to establish the opti-
mal regimen for HDCT.
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A LONG-TERM EXPERIENCE USING AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR THE MANAGMENT OF HODGKIN’S LYMPHOMA
Skikne, B.1, Divine1, C.1, Thudi, N.1, Deauna-Limayo, D.1,
Bodensteiner, D.1, Ganguly, S.1, Williams, C.2, Abhyankar, S.2,
McGuirk, J.2 1. The University of Kansas Medical Center, Kansas City,
KS; 2. Kansas City Cancer Center, Kansas City, MO.
Hodgkin’s disease (HD) patients generally have a good long-
term prognosis with approximately 70% cure rate. However, the
prognosis signiﬁcantly declines after disease relapse. High-dose
chemotherapy with autologous stem cell transplantation is an ef-
fective salvage option for patients in relapse with 5-year OS of
50%, and has become an accepted therapy. While transplantation
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